| 25-5989 |
Chian Chiu Li v. Apple, Inc. |
Federal Circuit |
2025-10-29 |
Denied |
Response WaivedIFP |
enablement negative-limitation patent-law specification-requirement statutory-interpretation written-description |
Whether, under 35 U.S.C. § 112(a), a patent specification must include a written description supporting a claimed negative limitation |
| 22-671 |
Novartis Pharmaceuticals Corporation v. HEC Pharm Co., Ltd., et al. |
Federal Circuit |
2023-01-20 |
Denied |
Amici (3) |
28-usc-46 appellate-procedure case-law judicial-administration judicial-review panel-composition patent-law statutory-interpretation written-description |
Whether 28 U.S.C. §46 and principles of sound judicial administration preclude a court of appeals from adding a new judge to form a new panel and rede… |
| 21-1567 |
Biogen International GmbH, et al. v. Mylan Pharmaceuticals Inc. |
Federal Circuit |
2022-06-15 |
Denied |
Amici (2) |
35-usc-112 effective-dose efficacy-requirement federal-circuit multiple-sclerosis patent patent-law patent-specification statutory-interpretation written-description |
Is 35 U.S.C. § 112's written-description requirement met when the specification describes the invention? |
| 21-1566 |
Juno Therapeutics, Inc., et al. v. Kite Pharma, Inc. |
Federal Circuit |
2022-06-15 |
Denied |
Amici (5)Relisted (6) |
35-usc-112(a) enablement federal-circuit invention-scope inventor-possession patent patent-law patent-specification statutory-interpretation written-description |
Whether the written description requirement under 35 USC 112(a) should be measured by the statutory standard or the Federal Circuit's 'possession' tes… |
| 21-7010 |
Jabari J. Johnson v. James Johnson |
Tenth Circuit |
2022-01-31 |
Denied |
IFP |
35-usc-112 federal-circuit patent patent-act standing written-description |
Whether the U.S. Court of Appeals for the Federal Circuit erred in its interpretation of the Patent Act's written description requirement under 35 U.S… |
| 21-757 |
Amgen Inc., et al. v. Sanofi, et al. |
Federal Circuit |
2021-11-22 |
Judgment Issued |
CVSGAmici (33)Response RequestedRelisted (4) |
35-usc-112 claim-construction claim-scope enablement enablement-requirement invention-disclosure judicial-review patent patent-law statutory-interpretation undue-experimentation written-description |
Whether enablement is a question of fact or law |
| 20-380 |
Idenix Pharmaceuticals LLC, et al. v. Gilead Sciences, Inc. |
Federal Circuit |
2020-09-24 |
Denied |
Amici (3)Response RequestedResponse WaivedRelisted (2) |
35-usc-112a enablement genus-claim genus-claims patent patent-law pharmaceutical-innovation pharmaceuticals statutory-interpretation written-description |
Whether the Federal Circuit's genus-claim-specific enablement rule and separate 'possession' requirement are consistent with 35 U.S.C. § 112(a) |
| 20-74 |
Andrei Iancu, Under Secretary of Commerce for Intellectual Property and Director, United States Patent and Trademark Office v. Eugene H. Luoma, et al. |
Federal Circuit |
2020-07-27 |
GVR |
Response WaivedRelisted (2) |
administrative-law america-invents-act enablement intellectual-property judicial-review obviousness patent-eligibility patent-review patent-trial-and-appeal-board patent-validity prior-art written-description |
Whether the Patent Trial and Appeal Board's application of the statutory requirements for patentability under 35 U.S.C. §§ 101, 102, 103, and 112 was … |
| 19-1131 |
Actavis Laboratories FL, Inc. v. Nalpropion Pharmaceuticals LLC |
Federal Circuit |
2020-03-16 |
Denied |
Amici (1) |
35-usc-112 claim-construction federal-circuit patent-claims patent-law patent-law-35-usc-112 patent-specification patent-validity statutory-interpretation written-description written-description-requirement |
Whether § 112 requires a patent's specification to contain a written description of all of the limitations of a patent's claims, not just a 'substanti… |
| 19-584 |
Nuvo Pharmaceuticals (Ireland) Designated Activity Company, et al. v. Dr. Reddy's Laboratories Inc., et al. |
Federal Circuit |
2019-11-04 |
Denied |
Response Waived |
35-usc-112 enablement federal-circuit innovation patent patent-law pharmaceutical pharmaceutical-composition prior-art written-description |
Whether the Federal Circuit erred by holding that, whenever the prior art teaches away from a pharmaceutical composition, the written description of a… |
| 19-571 |
Intel Corporation, et al. v. Continental Circuits LLC |
Federal Circuit |
2019-10-31 |
Denied |
Amici (3)Response Waived |
claim-construction claim-interpretation claim-scope disclaimer disclaimer-doctrine federal-circuit ordinary-meaning patent patent-construction specification specification-analysis written-description |
Whether courts should construe a patent's claims in light of the written description of the invention disclosed in the patent's specification |
| 19-445 |
Neology, Inc. v. International Trade Commission, et al. |
Federal Circuit |
2019-10-03 |
Denied |
Response Waived |
clear-and-convincing-evidence due-process federal-circuit filing-date notice patent patent-claim patent-validity procedural-due-process validity written-description |
Whether a patent can be invalidated without notifying the patent owner about the specific invalidity challenge and giving the patent owner an opportun… |
| 19-211 |
Time Warner Cable, Inc., et al. v. Sprint Communications Company, L.P. |
Federal Circuit |
2019-08-19 |
Denied |
Amici (1) |
35-usc-112 35-usc-112a 35-usc-284 apportionment federal-circuit garretson-v-clark patent-claims patent-damages patent-infringement patent-validity reasonable-royalty written-description |
Whether the Federal Circuit erred by affirming a damages award based on unapportioned end-user service revenues |
| 18-1515 |
Eli Lilly and Company v. Erfindergemeinschaft UroPep GbR |
Federal Circuit |
2019-06-06 |
Denied |
Amici (3)Response RequestedResponse WaivedRelisted (2) |
35-usc-112 ariad-pharmaceuticals claim-construction enablement functional-claiming halliburton-oil-well-cementing halliburton-oil-well-cementing-co-v-walker halliburton-precedent patent-claims patent-eligibility patent-law point-of-novelty single-step-claim written-description |
Whether a single-step patent claim that describes its point of novelty solely in functional terms violates the rule against functional claiming |
| 18A1232 |
Time Warner Cable, Inc., et al. v. Sprint Communications Company, L.P. |
Federal Circuit |
2019-05-29 |
Presumed Complete |
|
apportionment federal-circuit jury-verdicts patent-damages patent-infringement written-description |
Whether the Federal Circuit improperly deviated from longstanding Supreme Court precedents on patent damages apportionment by authorizing unapportione… |
| 18-590 |
Cave Consulting Group, LLC v. OptumInsight, Inc. |
Federal Circuit |
2018-11-06 |
Denied |
Response Waived |
claim-language claim-scope judicial-construction lexicography-disavowal patent-claim-construction patent-scope patent-specification patent-validity public-notice specification specification-interpretation written-description |
May a court construe a patent claim in a way that contradicts its plain and ordinary meaning by relying on statements in the specification that do not… |
| 18-127 |
Amgen Inc., et al. v. Sanofi, et al. |
Federal Circuit |
2018-07-27 |
Denied |
Amici (1)Response RequestedRelisted (2) |
35-usc-112 biotechnology enablement federal-circuit innovation patent-law possession statutory-interpretation written-description |
Whether the standard for determining the adequacy of the 'written description of the invention' should be as the statute says—that the description mus… |